Search research articles
Contact Us
Filters
Showing results (491-500 of 703) with videos related to
Page
of 71
Sort By:
European Journal of Cancer (Oxford, England : 1990)
|
October 12, 2023
Long-term outcomes and persistent toxicities following BRAF/MEK inhibitor therapy for advanced melanoma
Rachel S Goodman, Lorenza Di Guardo, Andrea Maurichi, et al.
Annals of Surgical Oncology
|
May 18, 2024
The Effect of Neoadjuvant Systemic Therapy on Surgical Outcomes After Lymph Node Dissections for Stage III Melanoma; An Australian Cohort
Lisanne P Zijlker, Henry Chen, Andrew J Spillane, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
February 13, 2023
Nivolumab and Relatlimab in Patients With Advanced Melanoma That Had Progressed on Anti-Programmed Death-1/Programmed Death Ligand 1 Therapy: Results From the Phase I/IIa RELATIVITY-020 Trial
Paolo Antonio Ascierto, Evan J Lipson, Reinhard Dummer, et al.
The Lancet. Oncology
|
March 13, 2017
Binimetinib versus dacarbazine in patients with advanced NRAS-mutant melanoma (NEMO): a multicentre, open-label, randomised, phase 3 trial
Reinhard Dummer, Dirk Schadendorf, Paolo A Ascierto, et al.
European Journal of Cancer (Oxford, England : 1990)
|
November 29, 2024
Long-term outcomes among patients who respond within the first year to nivolumab plus ipilimumab or nivolumab monotherapy: A pooled analysis in 935 patients
C Robert, G V Long, J Larkin, et al.
The Lancet. Oncology
|
August 15, 2024
Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG/KEYNOTE-054): long-term, health-related quality-of-life results from a double-blind, randomised, controlled, phase 3 trial
Emanuel Bührer, Michal Kicinski, Mario Mandala, et al.
Cancer Immunology Research
|
September 12, 2020
Tumor Mutation Burden and Structural Chromosomal Aberrations Are Not Associated with T-cell Density or Patient Survival in Acral, Mucosal, and Cutaneous Melanomas
Jarem Edwards, Peter M Ferguson, Serigne N Lo, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
July 22, 2022
Phase II LEAP-004 Study of Lenvatinib Plus Pembrolizumab for Melanoma With Confirmed Progression on a Programmed Cell Death Protein-1 or Programmed Death Ligand 1 Inhibitor Given as Monotherapy or in Combination
Ana Arance, Luis de la Cruz-Merino, Teresa M Petrella, et al.
Nature Communications
|
November 8, 2018
Epigenetic profiling for the molecular classification of metastatic brain tumors
Javier I J Orozco, Theo A Knijnenburg, Ayla O Manughian-Peter, et al.
Clinical and Experimental Immunology
|
August 1, 2020
Mucosal-associated invariant T (MAIT) cells are activated in the gastrointestinal tissue of patients with combination ipilimumab and nivolumab therapy-related colitis in a pathology distinct from ulcerative colitis
S C Sasson, J J Zaunders, K Nahar, et al.
Page
of 71
Search research articles
Search
Showing results (491-500 of 703) with videos related to
Sort By:
Page
of 71
European Journal of Cancer (Oxford, England : 1990)
|
October 12, 2023
Long-term outcomes and persistent toxicities following BRAF/MEK inhibitor therapy for advanced melanoma
Rachel S Goodman, Lorenza Di Guardo, Andrea Maurichi, et al.
Annals of Surgical Oncology
|
May 18, 2024
The Effect of Neoadjuvant Systemic Therapy on Surgical Outcomes After Lymph Node Dissections for Stage III Melanoma; An Australian Cohort
Lisanne P Zijlker, Henry Chen, Andrew J Spillane, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
February 13, 2023
Nivolumab and Relatlimab in Patients With Advanced Melanoma That Had Progressed on Anti-Programmed Death-1/Programmed Death Ligand 1 Therapy: Results From the Phase I/IIa RELATIVITY-020 Trial
Paolo Antonio Ascierto, Evan J Lipson, Reinhard Dummer, et al.
The Lancet. Oncology
|
March 13, 2017
Binimetinib versus dacarbazine in patients with advanced NRAS-mutant melanoma (NEMO): a multicentre, open-label, randomised, phase 3 trial
Reinhard Dummer, Dirk Schadendorf, Paolo A Ascierto, et al.
European Journal of Cancer (Oxford, England : 1990)
|
November 29, 2024
Long-term outcomes among patients who respond within the first year to nivolumab plus ipilimumab or nivolumab monotherapy: A pooled analysis in 935 patients
C Robert, G V Long, J Larkin, et al.
The Lancet. Oncology
|
August 15, 2024
Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG/KEYNOTE-054): long-term, health-related quality-of-life results from a double-blind, randomised, controlled, phase 3 trial
Emanuel Bührer, Michal Kicinski, Mario Mandala, et al.
Cancer Immunology Research
|
September 12, 2020
Tumor Mutation Burden and Structural Chromosomal Aberrations Are Not Associated with T-cell Density or Patient Survival in Acral, Mucosal, and Cutaneous Melanomas
Jarem Edwards, Peter M Ferguson, Serigne N Lo, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
July 22, 2022
Phase II LEAP-004 Study of Lenvatinib Plus Pembrolizumab for Melanoma With Confirmed Progression on a Programmed Cell Death Protein-1 or Programmed Death Ligand 1 Inhibitor Given as Monotherapy or in Combination
Ana Arance, Luis de la Cruz-Merino, Teresa M Petrella, et al.
Nature Communications
|
November 8, 2018
Epigenetic profiling for the molecular classification of metastatic brain tumors
Javier I J Orozco, Theo A Knijnenburg, Ayla O Manughian-Peter, et al.
Clinical and Experimental Immunology
|
August 1, 2020
Mucosal-associated invariant T (MAIT) cells are activated in the gastrointestinal tissue of patients with combination ipilimumab and nivolumab therapy-related colitis in a pathology distinct from ulcerative colitis
S C Sasson, J J Zaunders, K Nahar, et al.
Page
of 71